Literature DB >> 27729673

Gefitinib and Sonidegib.

Corey J Medler1, J Aubrey Waddell1, Dominic A Solimando1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2015        PMID： 27729673      PMCID： PMC5057192          DOI： 10.1310/hpj5010-868

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  11 in total

1.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Authors:  J Baselga; D Rischin; M Ranson; H Calvert; E Raymond; D G Kieback; S B Kaye; L Gianni; A Harris; T Bjork; S D Averbuch; A Feyereislova; H Swaisland; F Rojo; J Albanell
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

2.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Authors:  Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

3.  Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.

Authors:  Jong-Mu Sun; Ki Hyeong Lee; Sang-We Kim; Dae Ho Lee; Young Joo Min; Hwan Jung Yun; Hoon Kyo Kim; Hong Suk Song; Yeul Hong Kim; Bong-Seog Kim; In Gyu Hwang; Keehyun Lee; Sook Jung Jo; Jae Won Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

4.  A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Authors:  Jordi Rodon; Hussein A Tawbi; Anne L Thomas; Ronald G Stoller; Christian P Turtschi; Jose Baselga; John Sarantopoulos; Devalingam Mahalingam; Yaping Shou; Melissa A Moles; Lin Yang; Camille Granvil; Eunju Hurh; Kristine L Rose; Dereck D Amakye; Reinhard Dummer; Alain C Mita
Journal:  Clin Cancer Res       Date:  2014-02-12       Impact factor: 12.531

5.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

6.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

7.  Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer.

Authors:  Alicia S Chen; Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2013-12

8.  Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.

Authors:  K Nakagawa; T Tamura; S Negoro; S Kudoh; N Yamamoto; N Yamamoto; K Takeda; H Swaisland; I Nakatani; M Hirose; R-P Dong; M Fukuoka
Journal:  Ann Oncol       Date:  2003-06       Impact factor: 32.976

9.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

10.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

Authors:  J-Y Douillard; G Ostoros; M Cobo; T Ciuleanu; R McCormack; A Webster; T Milenkova
Journal:  Br J Cancer       Date:  2013-11-21       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.